(+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys

Rupniak, N M; Boyce, S; Steventon, M J; Iversen, S D
July 1990
Journal of Neurology, Neurosurgery & Psychiatry;Jul1990, Vol. 53 Issue 7, p622
Academic Journal
No abstract available.


Related Articles

  • L-Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Pearce, R. K. B.; Heikkilä, M.; Lindén, I.-B.; Jenner, P. // Psychopharmacology;2001, Vol. 156 Issue 4, p402 

    Rationale: L-Dopa induces dyskinesias during the treatment of Parkinson's disease and also in primates with nigrostriatal lesions produced by MPTP, but it is claimed that L-dopa does not provoke dyskinesia in humans or monkeys with an intact or mildly damaged nigrostriatal system. Objectives:...

  • Cholinergic manipulation of motor disability and l-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. Jackson, M.; Swart, T.; Pearce, R.; Jenner, P. // Journal of Neural Transmission;Feb2014, Vol. 121 Issue 2, p163 

    Anti-cholinergic drugs are used in the treatment of Parkinson's disease (PD) and they can improve motor disability in some patients and may alter the expression of dyskinesia. We report the effects of anti-cholinergic and pro-cholinergic agents administered alone and combined with l-DOPA, on...

  • Actions of the D[sub 1] agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Pearce, R. K. B.; Jackson, M.; Britton, D. R.; Shiosaki, K.; Jenner, P.; Marsden, C. D. // Psychopharmacology;1999, Vol. 142 Issue 1, p51 

    Abstract Common marmosets show parkinsonian motor deficits following 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) administration and develop dyskinesias during chronic L-dopa exposure. The D[sub l] agonists A-77636 [(1R, 3S) 3-(l'-adamantyl)-l-aminomethyl-3, 4-dihydro-5,...

  • Imaging Nicotine- and Amphetamine-Induced Dopamine Release in Rhesus Monkeys with [11C]PHNO vs [11C]raclopride PET. Gallezot, Jean-Dominique; Kloczynski, Tracy; Weinzimmer, David; Labaree, David; Zheng, Ming-Qiang; Lim, Keunpoong; Rabiner, Eugenii A; Ridler, Khanum; Pittman, Brian; Huang, Yiyun; Carson, Richard E; Morris, Evan D; Cosgrove, Kelly P // Neuropsychopharmacology;Mar2014, Vol. 39 Issue 4, p866 

    The radiotracer [11C]PHNO may have advantages over other dopamine (DA) D2/D3 receptor ligands because, as an agonist, it measures high-affinity, functionally active D2/D3 receptors, whereas the traditionally used radiotracer [11C]raclopride measures both high- and low-affinity receptors. Our aim...

  • The Thatcher illusion in squirrel monkeys ( Saimiri sciureus). Nakata, Ryuzaburo; Osada, Yoshihisa // Animal Cognition;Jul2012, Vol. 15 Issue 4, p517 

    Like humans, Old World monkeys are known to use configural face processing to distinguish among individuals. The ability to recognize an individual through the perception of subtle differences in the configuration of facial features plays an important role in social cognition. To test this...

  • Dopamine Transporter Binding Is Unaffected by L-DOPA Administration in Normal and MPTP-Treated Monkeys. Fernagut, Pierre-Olivier; Qin Li; Dovero, Sandra; Piu Chan; Tao Wu; Ravenscroft, Paula; Hill, Michael; Zhenwen Chen; Bezard, Erwan // PLoS ONE;2010, Vol. 5 Issue 11, p1 

    Background: Radiotracer imaging of the presynaptic nigrostriatal dopaminergic system is used to assess disease progression in Parkinson's disease (PD) and may provide a useful adjunct to clinical assessment during therapeutic trials of potential neuroprotective agents. Several clinical trials...

  • antiparkinsonian.  // Taber's Cyclopedic Medical Dictionary;2005, p140 

    A definition of the medical term "antiparkinsonian" is presented, which means an agent effective against parkinsonism.

  • A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Stéphanie Mounayar; Sabrina Boulet; Dominique Tandé; Caroline Jan; Mathias Pessiglione; Etienne C. Hirsch; Jean Féger; Marc Savasta; Chantal François; Léon Tremblay // Brain: A Journal of Neurology;Nov2007, Vol. 130 Issue 11, p2898 

    The cardinal symptoms in Parkinsons disease (PD), akinesia, rigidity and tremor, are only observed when the striatal level of dopamine is decreased by 60–80%. During the preclinical phase of PD, compensatory mechanisms are probably involved in delaying the appearance of motor symptoms. In...

  • Dyskinesia in Parkinson Disease - An Unmet Therapeutic Challenge. Debicki, Derek; Jog, Mandar // Canadian Journal of Neurological Sciences;Jul2012, Vol. 39 Issue 4, p414 

    The author discusses levodopa-induced dyskinesias(LID). It states that LID are involuntary movements including chorea, dystonia, myoclonus or ballism, which can occur at peak drug effect, as the drug effect is decreases throughout the dose period.Treatment of LID in Parkinson's disease(PD)...

  • Photo brief.  // Science Teacher;Dec96, Vol. 63 Issue 9, p12 

    Presents a photograph of the Amazon squirrel monkey which lives in the fast disappearing tropical rain forests in the world.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics